Skip to content
Screener

Beam Therapeutics BEAM Q4 2025 Annual earnings

Reported February 24, 2026 · Before market open

Revenue$114.1MBeat by $102.4M
EPS-$0.10Beat by $1.03
Revenue estimate$11.7M
EPS estimate-$1.13

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$8.8M
EPS estimate-$1.16

Financials

Q4 2025

Income statement

See full
Revenue$114.1M+280%
Operating income-$17.4M+82.6%

Balance sheet

See full
Cash & equivalents$294.9M+4.6%
Total debt$154.1M-4.5%
Total equity$1.2B+68.8%
Total assets$1.5B+34.2%

Cash flow

See full
Operating cash flow-$83.3M-9.1%
CapEx$3.7M+25.7%
Free cash flow-$87.0M-9.7%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$2.81B+37.0%
Enterprise value$2.67B+38.2%
P/S20.1×-12.2×

Profitability

See full
Operating margin-274.6%-101pp
FCF margin-257.7%-90.4pp

Returns & leverage

See full
Debt / equity0.1×-0.1×
Current ratio13.1×+8.3×

FAQ

When did Beam Therapeutics report Q4 2025 earnings?
Beam Therapeutics (BEAM) reported Q4 2025 earnings on February 24, 2026 before market open.
What were Beam Therapeutics's Q4 2025 revenue and EPS?
Beam Therapeutics reported revenue of $114.1M and eps of $-0.10 for Q4 2025.
Did Beam Therapeutics beat estimates in Q4 2025?
Revenue beat the consensus estimate of $11.7M by $102.4M. EPS beat the consensus estimate of $-1.13 by $1.03.
How did Beam Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 279.5% from $30.1M a year earlier and eps grew 90.8% from $-1.09.
Where can I find Beam Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-065191) and the 10-K periodic report (0001193125-26-065194) directly on SEC EDGAR. The filing index links above go to sec.gov.